Skip to content

AnaptysBio, Inc. ANAB Increase (Decrease) in Deferred Income Taxes

Increase (Decrease) in Deferred Income Taxes at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$96M-31.0%
Eli Lilly logo
Eli LillyLLY
ADMA Biologics logo
ADMA BiologicsADMA

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredIncomeTaxes.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s increase (decrease) in deferred income taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s increase (decrease) in deferred income taxes?
AnaptysBio, Inc. (ANAB) reported increase (decrease) in deferred income taxes of -$0 in Q1 2026.